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background: Transcatheter aortic valve replacement (TAVR) is an alternative to surgical aortic-valve replacement (SAVR) for high-risk 
patients with severe aortic stenosis (AS). Our objective was to evaluate the efficacy and safety of TAVR compared with SAVR in high-risk 
patients with AS.
methods: We conducted electronic searches of randomized controlled trials (RCT). The primary endpoint was all-cause mortality. 
Secondary endpoints were myocardial infarction (MI), stroke, major bleeding, vascular complications, aortic regurgitation (AR), acute 
kidney injury (AKI) and permanent pacemaker implantation (PPM). Odds ratios (OR) and 95% confidence intervals (CI) computed using the 
Mantel-Haenszel (MH) method. Fixed-effect model was used; if heterogeneity (I2)>40, effects were obtained using a random model.
results: Three RCT (STACCATO, PARTNER B and Core Valve) were included, with a total of 1,516 patients. No difference was found 
for all-cause mortality at 30-days and 1-year follow up (Figure). We only identified significant difference in the incidence of vascular 
complications (OR 3,56 [95% CI 2.12-5.97], p <0.001) and PPM (OR 1.97 [95% CI 1.39-2.79], p <0.001) with TAVR. SAVR patients 
experienced higher major bleeding (OR 0.63 [95% CI 0.49-0.8], p <0.001). Exclusion of a single study from the analysis did not alter the 
overall result.
Conclusion:  Our meta-analysis showed that TAVR as effective as SAVR in high-risk patient with AS. Each intervention convenes its own 
significant complications.
 
